This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Recovery in Drugs Sales to Aid AbbVie's (ABBV) Q3 Earnings
by Zacks Equity Research
AbbVie (ABBV) is expected to have witnessed a recovery in demand trends of new drugs amid the receding impact of the pandemic. However, sales of physician-administered drugs are likely to have been hurt by the residual impact.
Healthcare ETFs in Focus as Q3 Earnings Unfold
by Sweta Killa
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MGV
Is WisdomTree U.S. Total Dividend ETF (DTD) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DTD
AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
AbbVie's (ABBV) third-quarter results are expected to reflect the impact of a strong recovery in demand for new drugs. Investors are likely to focus on any update related to guidance.
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Should WisdomTree U.S. LargeCap Dividend ETF (DLN) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DLN
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Buy This Great High-Yield Dividend Stock?
by Benjamin Rains
Investors in search of stable income should consider strong dividend-paying stocks, with solid yields. Pharmaceutical standout AbbVie appears to be worth buying as a long-term play, with it set to release its Q3 results on Friday, October 29...
The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Tesla, Johnson & Johnson, PayPal, Verizon, Square and GlaxoSmithKline
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VONV
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should Oshares U.S. Quality Dividend ETF (OUSA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for OUSA
Top Analyst Reports for Tesla, Johnson & Johnson & PayPal
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Johnson & Johnson (JNJ), and PayPal Holdings, Inc. (PYPL).
Pharma Stock Roundup: JNJ Mixed Q3 Results, FDA Nod to Mix & Match COVID Boosters
by Kinjel Shah
J&J (JNJ) beats estimates for earnings but misses the same for sales. FDA authorizes mix and match of COVID vaccine boosters.
Pfizer's (PFE) Comirnaty Booster Dose Achieves 95.6% Efficacy
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce promising data from a late-stage study evaluating the booster dose of their COVID-19 vaccine, Comirnaty.
Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Fastly, PagerDuty, Johnson & Johnson, Moderna and Pfizer highlighted as Zacks Bull and Bear of the Day
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Can Biotech ETFs Gain From Positive Booster Update?
by Sweta Jaiswal, FRM
In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.
Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports
by Zacks Equity Research
Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.
FDA Approves JNJ & MRNA's COVID-19 Boosters & Mixing of Doses
by Indrajit Bandyopadhyay
The FDA authorizes booster doses of COVID-19 vaccines of JNJ and MRNA. It also authorizes a heterologous boosting option which will allow administration of booster dose of any available vaccine irrespective of the primary vaccination regimen.
JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus
by Sweta Killa
Johnson & Johnson (JNJ) continued its long streak of earnings beat but lagged the revenue estimates. The company lifted its full-year guidance.
Biogen (BIIB) Q3 Earnings Top, Aduhelm Sales Negligible
by Zacks Equity Research
Biogen (BIIB) beats third-quarter estimates for both earnings and sales and ups its financial guidance for 2021.
Stock Market News for Oct 20, 2021
by Zacks Equity Research
The S&P 500 and Nasdaq recoded the largest four consecutive winning stretch since July, lifted by an encouraging third-quarter corporate earnings result.